Today, we announced the final results of our Phase 1 study of CBX-12 in patients with advanced or metastatic solid tumors, which were presented at ESMO - European Society for Medical Oncology. The data demonstrate the broad activity of CBX-12 across six tumor types, with a strong response rate in TOP1-naive patients with ovarian and breast cancer, in addition to a favorable safety profile. Based on this positive data, we have initiated a Phase 2 study of CBX-12 in platinum-resistant ovarian cancer. Read more about CBX-12’s potential for precision targeting and full results: https://bit.ly/3XqMkku #ESMO24 #Oncology #ClinicalTrials
Cybrexa Therapeutics
Biotechnology Research
New Haven, CT 4,460 followers
Changing the paradigm for cancer treatment through the development of antigen-independent peptide drug conjugates.
About us
Cybrexa is a clinical-stage oncology biotechnology company developing novel antigen-independent peptide drug conjugates (ADCs) aimed at combatting a range of cancer types, including ovarian, breast and non-small cell lung cancer. With the potential to disrupt the standard of care, the Cybrexa alphalex™ technology is a novel antigen-independent peptide drug conjugate (PDC) platform that enables targeted delivery of highly potent anticancer treatments and aims to revolutionize the standard of care in oncology. The platform consists of a pHLIP® peptide, linker, and small molecule anti-cancer agent. pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces. pHLIP® was developed at Yale University and the University of Rhode Island, and is exclusively licensed to pHLIP, Inc. alphalex™ represents the disruptive next generation in tumor targeting. Early clinical trials of the company’s lead candidate, CBX-12, demonstrate robust efficacy signals and tolerability in patients with metastatic cancer. As a privately held company, Cybrexa is led by a management team experienced at building life science companies and driven by scientists with an expertise in drug development and oncology. For more information, visit www.cybrexa.com. Community Guidelines: https://bit.ly/3GI6AU0
- Website
-
http://www.cybrexa.com
External link for Cybrexa Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- New Haven, CT
- Type
- Privately Held
- Founded
- 2017
- Specialties
- biotech, oncology, Phase I, PARP inhibitor, DDR, and drug development
Locations
-
Primary
Get directions
5 Science Park
New Haven, CT 06511, US
Employees at Cybrexa Therapeutics
Updates
-
We look forward to presenting full results from our Phase 1 study of peptide drug conjugate CBX-12 in advanced solid tumors at ESMO - European Society for Medical Oncology. As an antigen-independent therapy, CBX-12 may have broad utility in patients who are not eligible for antigen-targeted therapies. Join us at 12pm CET on Saturday, Sept 14, to learn more: https://bit.ly/3AY8P8K #oncology #ESMO24
-
-
#Cybrexa is leading the way in developing revolutionary therapies that target tumors while sparing healthy tissue. Our innovative alphalex™ platform provides a new way to deliver drugs directly into cancer cells without depending on surface antigens. This cutting-edge approach has the potential to improve current #cancertherapeutics. We are dedicated to developing innovative solutions for patients fighting cancer. Stay tuned for some exciting clinical updates. Learn more about our advanced research and technology: http://bit.ly/3yCiugx. #drugdiscovery #smallmolecules #peptidedrugconjugates #oncology #lifesciences #WeAreCybrexa
-
Cybrexa Therapeutics reposted this
At #Cybrexa, we are steadfastly committed to developing bold, innovative therapies that have the potential to shift the treatment paradigm. #DYK, our team of highly skilled scientists and clinical professionals is pioneering a platform of #cancertherapeutics designed to target tumors while sparing healthy tissue. This refined approach to intracellular delivery aims to enhance existing therapies and pave the way for new ones. Learn more: 👉 http://bit.ly/3yB7osv. #drugdiscovery #smallmolecules #peptidedrugconjugates #oncology #lifesciences #CTBiotech #WeAreCybrexa
-
At #Cybrexa, we are steadfastly committed to developing bold, innovative therapies that have the potential to shift the treatment paradigm. #DYK, our team of highly skilled scientists and clinical professionals is pioneering a platform of #cancertherapeutics designed to target tumors while sparing healthy tissue. This refined approach to intracellular delivery aims to enhance existing therapies and pave the way for new ones. Learn more: 👉 http://bit.ly/3yB7osv. #drugdiscovery #smallmolecules #peptidedrugconjugates #oncology #lifesciences #CTBiotech #WeAreCybrexa
-
Happy #IndependenceDay! Today, we proudly celebrate the freedom and independence made possible by the brave men and women who have fought, and continue to fight, for our country. #FourthofJuly #WeAreCybrexa
-
#NEWS: Cybrexa Therapeutics today announced the appointment of former founding Alnylam CEO, John Maraganore, Ph.D., as Strategic Advisor to the Company’s Executive Leadership Team. In this role, Dr. Maraganore will provide strategic guidance, leveraging his extensive experience in the biopharma industry to support the advancement of #Cybrexa’s lead candidate and alphalex™ technology platform. To read the press release in full, click here: https://bit.ly/4eAIIEa. #drugdiscovery #smallmolecules #peptidedrugconjugates #cancertherapeutics #CTBiotech #WeAreCybrexa
-
-
#DYK that while the #Cybrexa headquarters and most of our team members reside in #Connecticut, many of our dedicated and talented colleagues are located in several states across the US, including Florida, Georgia, Massachusetts, New Hampshire, New Jersey, Rhode Island, and Texas? Regardless of the distance, Cybrexa’s commitment to advancing our pipeline of #cancertherapeutics unites our team members as we work hard to bring hope to the #oncology community. Last month, some of our team members proudly wore teal ribbons on #WorldOvarianCancerDay to show solidarity and raise awareness for #ovariancancer. Check them out below. 👇 #CTBiotech #drugdiscovery #smallmolecules #peptidedrugconjugates #WeAreCybrexa
-
On this #MemorialDay, we honor those who made the ultimate sacrifice to defend our country and uphold our freedom. We pay tribute to their selflessness and remember their legacy. We wish everyone a safe and meaningful Memorial Day weekend. #MDW24
-
-
At #Cybrexa, we are committed to building a robust portfolio of powerful #oncology therapeutics to address the urgent need for more cutting-edge therapies. Leveraging the capabilities of our alphalex™ technology, we strive to develop innovative, tumor-targeted anti-cancer agents that have the potential to revolutionize cancer treatment. To learn more about our efforts, visit: http://bit.ly/3yCiugx. #drugdiscovery #smallmolecules #peptidedrugconjugates #WeAreCybrexa